Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden

被引:29
作者
Graf, LL
Welsh, CH
Qamar, Z
Marlar, RA
机构
[1] Denver Vet Affairs Med Ctr, Pathol Res Lab, Res Serv, Denver, CO USA
[2] Denver Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Med Serv, Denver, CO USA
[3] Denver Vet Affairs Med Ctr, Pathol Res Lab, Pathol & Lab Med Serv, Denver, CO USA
[4] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA
[5] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA
[6] Univ Colorado, Hlth Sci Ctr, Dept Biochem, Denver, CO 80262 USA
[7] Aga Khan Univ, Sch Med, Karachi, Pakistan
关键词
activated protein C resistance; case-control study; factor V Leiden; factor VIII; HR2; haplotype; venous thromboembolism;
D O I
10.1309/QCUUNRMVJY8MWPPL
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Activated protein C (APC) resistance is a common risk factor for venous thromboembolism (VTE) attributed to various mechanisms, including factor V Leiden (FVL) polymorphism. FVL is considered responsible for up to 95% of APC resistance; however, other factor V polymorphisms and elevated factor VIII levels also have been implicated. We assessed whether additional mechanisms contribute to APC resistance in a blinded case-control study of 65 subjects by measuring APC resistance using 3 methods: 2 activated partial thromboplastin time-based methods with and without dilution in factor V-deficient plasma and I Russell viper venom-based assay (RVV). Without factor V-deficient plasma, 24 subjects were APC resistant; with factor V-deficient plasma, the assay identified fewer APC-resistant subjects, as did RVV All assays detected the 7 heterozygous FVL subjects. Thirteen subjects had factor VIII levels above 150% (1.50). After excluding subjects with FVL or elevated factor VIII levels, 4 subjects still had APC resistance. VTE risk trended higher for subjects with APC resistance in the absence of FVL. Measurement of APC resistance without dilution in factor V-deficient plasma is needed to assess for potentially important, thrombotic risk factors other than FVL.
引用
收藏
页码:52 / 60
页数:9
相关论文
共 39 条
[1]  
Adcock DM, 1997, AM J CLIN PATHOL, V107, P105
[2]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[3]   A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype [J].
Bernardi, F ;
Faioni, EM ;
Castoldi, E ;
Lunghi, B ;
Castaman, G ;
Sacchi, E ;
Mannucci, PM .
BLOOD, 1997, 90 (04) :1552-1557
[4]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[5]   Syndromes of thrombosis and hypercoagulability - Congenital and acquired causes of thrombosis [J].
Bick, RL ;
Kaplan, H .
MEDICAL CLINICS OF NORTH AMERICA, 1998, 82 (03) :409-+
[6]  
Castaman G, 2000, THROMB HAEMOSTASIS, V84, P357
[7]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[8]  
DAHLBACK B, 1995, THROMB HAEMOSTASIS, V74, P139
[9]   Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation [J].
de Ronde, H ;
Bertina, RM .
BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (01) :7-17
[10]  
de Visser MCH, 2000, THROMB HAEMOSTASIS, V83, P577